Rituximab tops other disease-modifying tx options in MS

January 9, 2018

(HealthDay)—Rituximab has better efficacy and lower discontinuation rates than other disease-modifying treatment (DMT) choices for newly diagnosed relapsing-remitting multiple sclerosis (RRMS), according to a study published online Jan. 8 in JAMA Neurology.

Mathias Granqvist, M.D., from the Karolinska Institutet in Stockholm, and colleagues conducted a using prospectively collected data for patients in Sweden with newly diagnosed RRMS. The effectiveness and drug discontinuation rates of rituximab were compared with those of injectable DMTs, , fingolimod, and natalizumab.

Of the 494 patients, 43.5 percent received an injectable DMT, 17.4 percent dimethyl fumarate, 3.4 percent fingolimod, 10.1 percent natalizumab, 24.3 percent rituximab, and 1.2 percent other DMT. The researchers found that there were pronounced regional preferences, with 81 and 18 percent of patients in Västerbotten and Stockholm, respectively, receiving rituximab. The annual discontinuation rates were 0.03, 0.53, 0.32, 0.38, and 0.29 for rituximab, injectable DMTs, dimethyl fumarate, fingolimod, and natalizumab, respectively. The main reason for discontinuation of injectable DMTs, dimethyl fumarate, and fingolimod was continued disease activity; the main reason for discontinuation of natalizumab was positive John Cunningham virus serology results. Compared with injectable DMTs and dimethyl fumarate, the rates of clinical relapse and/or neuroradiologic disease activity were significantly lower for rituximab, with a tendency for lower relapse rates relative to and .

"Collectively, our findings suggest that rituximab performs better than other commonly used DMTs in patients with newly diagnosed RRMS," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Biogen, which manufactures .

Explore further: Rituximab effective for lupus-associated cytopenia

More information: Abstract/Full Text

Related Stories

Rituximab effective for lupus-associated cytopenia

December 27, 2017
(HealthDay)—Rituximab treatment seems effective for systemic lupus erythematosus (SLE)-associated immune cytopenias, with an overall initial response rate of 86 percent, according to a study published online Dec. 16 in ...

PFS up with obinutuzumab-based Tx in follicular lymphoma

October 5, 2017
(HealthDay)—For patients with follicular lymphoma, obinutuzumab-based immunochemotherapy is associated with longer progression-free survival than rituximab-based therapy, according to a study published online Oct. 4 in ...

Natalizumab shows promise for teens with multiple sclerosis

February 22, 2013
(HealthDay)—Natalizumab may be safe in pediatric multiple sclerosis (MS) patients with highly active disease, according to a small study published online Feb. 18 in JAMA Neurology.

Adding rituximab to chemo ups event-free survival in ALL

September 20, 2016
(HealthDay)—For young adults with acute lymphoblastic leukemia (ALL), adding rituximab to chemotherapy is associated with increased event-free survival, according to a study published in the Sept. 15 issue of the New England ...

Dimethyl fumarate linked to development of PML

April 9, 2015
(HealthDay)—An active ingredient in some psoriasis and multiple sclerosis medications, dimethyl fumarate, has been linked to two cases of progressive multifocal leukoencephalopathy (PML), according to two letters published ...

Tocilizumab treats rheumatoid arthritis after non-TNFi failure

March 30, 2016
(HealthDay)—For patients with rheumatoid arthritis (RA) and a first non-tumor necrosis factor inhibitor (TNFi) failure, treatment with tocilizumab seems more efficacious than abatacept or rituximab, according to a study ...

Recommended for you

Wiring diagram of the brain provides a clearer picture of brain scan data

December 14, 2018
Already affecting more than five million Americans older than 65, Alzheimer's disease is on the rise and expected to impact more than 13 million people by 2050. Over the last three decades, researchers have relied on neuroimaging—brain ...

Scientists identify method to study resilience to pain

December 14, 2018
Scientists at the Yale School of Medicine and Veterans Affairs Connecticut Healthcare System have successfully demonstrated that it is possible to pinpoint genes that contribute to inter-individual differences in pain.

Parents' brain activity 'echoes' their infant's brain activity when they play together

December 13, 2018
When infants are playing with objects, their early attempts to pay attention to things are accompanied by bursts of high-frequency activity in their brain. But what happens when parents play together with them? New research, ...

In the developing brain, scientists find roots of neuropsychiatric diseases

December 13, 2018
The most comprehensive genomic analysis of the human brain ever undertaken has revealed new insights into the changes it undergoes through development, how it varies among individuals, and the roots of neuropsychiatric illnesses ...

Researchers find the cause of and cure for brain injury associated with gut condition

December 13, 2018
Using a mouse model of necrotizing enterocolitis (NEC)—a potentially fatal condition that causes a premature infant's gut to suddenly die—researchers at Johns Hopkins say they have uncovered the molecular causes of the ...

Researchers discover abundant source for neuronal cells

December 13, 2018
USC researchers seeking a way to study genetic activity associated with psychiatric disorders have discovered an abundant source of human cells—the nose.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.